Global Ophthalmology Drugs Market Research Report, Global Ophthalmology Drugs Market

MenuMenu

Ophthalmology Drugs Global Market Forecast To 2022

REQUEST FOR SAMPLE REPORT

Asia Pacific was the largest region in the global ophthalmology drugs market, accounting for 36% of the market in 2018. North America was the second largest region accounting for 27% of the global ophthalmology drugs market. Africa was the smallest region in the global ophthalmology drugs market.

Drug manufacturers are developing new class of compounds called Rho-kinase inhibitors for the treatment of glaucoma. Rho-kinase pathway is an integral part of cellular functions such as contraction of vascular smooth muscle cells, organization of the actin cytoskeleton, cell adhesion and motility and gene expression. These inhibitors are different from widely used prostaglandin analogs because they target the outflow through trabecular meshwork rather than the uveoscleral outflow. Rho-kinase inhibitors have proved to decrease intraocular pressure by 25% to 30% with duration of action of 10 to 12 hours, which is more effective than the previous generation of drugs for this condition. Major Rho-kinase inhibitors being developed include ATS907, ATS8535, AR-12286, AR-13324, AMA0076 and BOL-303259-X.

Tags: , , ,

scroll to top